Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
3 Ro5 violations · MW 1,755.66 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | Observation Telavancin has poor bioavailability and must be administered over 30-120 minutes IV. | Reported | PepTherDia curated product PK field | Route: IV · 85 · Telavancin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 51000 ng*h/mL | Comparable | AUC (0 to 24 hrs) in human at 10 mg/kg once daily · human | area under curve · AUC· AUC (0 to 24 hrs) in human at 10 mg/kg once daily · Exact ChEMBL... | Open |
| 2 | 785000 ng*h/mL | Comparable | AUC (0 to 24) in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion · human | Route: iv · area under curve · AUC· AUC (0 to 24) in healthy human at 10 mg/kg, iv once daily for 3 d... | Open |
| 3 | 17304 ng*h/mL | Comparable | AUC (infinity) in CD1 mouse at 5 mg/kg, iv · mouse | Route: iv · area under curve · AUC· AUC (infinity) in CD1 mouse at 5 mg/kg, iv · Exact ChEMBL pref na... | Open |
| 4 | 785000 ng*h/mL | Comparable | AUC in human at 10 mg/kg, iv administered every 24 hrs · human | Route: iv · area under curve · AUC· AUC in human at 10 mg/kg, iv administered every 24 hrs · Exact Ch... | Open |
| 5 | 604000 ng*h/mL | Comparable | AUC in human at 7.5 mg/kg, iv administered every 24 hrs · human | Route: iv · area under curve · AUC· AUC in human at 7.5 mg/kg, iv administered every 24 hrs · Exact C... | Open |
| 6 | 269800 ng*h/mL | Comparable | AUC in rabbit at 15 mg/kg, iv · rabbit | Route: iv · area under curve · AUC· AUC in rabbit at 15 mg/kg, iv · Exact ChEMBL pref name TELAVANCIN... | Open |
| 7 | 638000 ng*h/mL | Comparable | AUC in rabbit at 7.5 mg/kg, iv administered once daily · rabbit | Route: iv · area under curve · AUC· AUC in rabbit at 7.5 mg/kg, iv administered once daily · Exact Ch... | Open |
| 8 | 17143 ng*h/mL | Comparable | AUClast in CD1 mouse at 5 mg/kg, iv · mouse | Route: iv · area under curve · AUC· AUClast in CD1 mouse at 5 mg/kg, iv · Exact ChEMBL pref name TELA... | Open |
| 9 | 780 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table auc 0 24 multiple dose · Table 8: Ph... | Open |
| 10 | 666 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table auc 0 24 single dose · Table 8: Phar... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 66072.02 nM | Comparable | Cmax in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion · human | Route: iv · max concentration · Cmax· Cmax in healthy human at 10 mg/kg, iv once daily for 3 days mea... | Open |
| 2 | 2961.85 nM | Comparable | Cmax in human at 10 mg/kg once daily · human | max concentration · Cmax· Cmax in human at 10 mg/kg once daily · Exact ChEMBL pref name T... | Open |
| 3 | 50693.19 nM | Comparable | Cmax in human at 7.5 mg/kg, iv administered every 24 hrs · human | Route: iv · max concentration · Cmax· Cmax in human at 7.5 mg/kg, iv administered every 24 hrs · Exac... | Open |
| 4 | 51262.77 nM | Comparable | Cmax in human plasma · human · plasma | max concentration · Cmax· Cmax in human plasma · Exact ChEMBL pref name TELAVANCIN · http... | Open |
| 5 | 34175.18 nM | Comparable | Cmax in human serum at 7.5 mg/kg · human · serum | max concentration · Cmax· Cmax in human serum at 7.5 mg/kg · Exact ChEMBL pref name TELAV... | Open |
| 6 | 64932.85 nM | Comparable | Cmax in rabbit at 10 mg/kg, iv administered once daily · rabbit | Route: iv · max concentration · Cmax· Cmax in rabbit at 10 mg/kg, iv administered once daily · Exact... | Open |
| 7 | 51262.77 nM | Comparable | Cmax in rabbit at 7.5 mg/kg, iv administered once daily · rabbit | Route: iv · max concentration · Cmax· Cmax in rabbit at 7.5 mg/kg, iv administered once daily · Exact... | Open |
| 8 | 108 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table cmax multiple dose · Table 8: Pharma... | Open |
| 9 | 93.6 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table cmax single dose · Table 8: Pharmaco... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1 hr 3600 seconds | Comparable | Tmax in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion · human | Route: iv · time to max concentration · Tmax· Tmax in healthy human at 10 mg/kg, iv once daily for 3... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 133 mL/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table vss multiple dose · Table 8: Pharmac... | Open |
| 2 | 145 mL/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table vss single dose · Table 8: Pharmacok... | Open |
| 3 | 0.52 L/kg | Comparable | Volume of distribution at steady state in CD1 mouse at 5 mg/kg, iv · mouse | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in CD1 mouse at 5 m... | Open |
| 4 | 0.122 L/kg | Comparable | Volume of distribution at steady state in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in healthy human at... | Open |
| 5 | 0.11 L/kg | Comparable | Volume of distribution at steady state in human after iv administration · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 90 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin mean protein binding approx · The mean bin... | Open |
| 2 | 90 % | Comparable | Plasma protein binding in healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days · human · plasma | Route: iv · plasma protein binding · PPB· Plasma protein binding in healthy human undergoing fiber-op... | Open |
| 3 | 90 % | Comparable | Plasma protein binding in human plasma at 750 mg administered as single dose · human · plasma | plasma protein binding · PPB· Plasma protein binding in human plasma at 750 mg administer... | Open |
| 4 | 90 % | Comparable | Protein binding healthy human serum · human · serum | plasma protein binding · PPB· Protein binding healthy human serum · Exact ChEMBL pref nam... | Open |
| 5 | 90 % | Comparable | Protein binding in human plasma · human · plasma | plasma protein binding · PPB· Protein binding in human plasma · Exact ChEMBL pref name TE... | Open |
| 6 | 95 % | Comparable | Protein binding in mouse plasma at 0.1 to 100 ug/mL by equilibrium dialysis · mouse · plasma | plasma protein binding · PPB· Protein binding in mouse plasma at 0.1 to 100 ug/mL by equi... | Open |
| 7 | > 90 % | Reported | PepTherDia curated product PK field · plasma protein | Route: IV · 85 · Telavancin · exact product name match · exact or normalized match | Open |
| 8 | Observation The mean binding is approximately 90% and is not affected by renal or hepatic impairment. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin binding not affected by impairment text ·... | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.2167 mL/min/kg | Comparable | Clearance at steady state in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion · human | Route: iv · clearance · CL· Clearance at steady state in healthy human at 10 mg/kg, iv once daily for... | Open |
| 2 | 5.1 mL/min/kg | Comparable | Clearance in CD1 mouse at 5 mg/kg, iv · mouse | Route: iv · clearance · CL· Clearance in CD1 mouse at 5 mg/kg, iv · Exact ChEMBL pref name TELAVANCIN... | Open |
| 3 | 0.2 mL/min/kg | Comparable | Clearance in human after iv administration · human | Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name TELAV... | Open |
| 4 | 13.1 mL/h/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table clearance multiple dose · Table 8: P... | Open |
| 5 | 13.9 mL/h/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Telavancin· 12.3 Pharmacokinetics · telavancin table clearance single dose · Table 8: Pha... | Open |
| 6 | Observation The clearance of telavancin is not expected to be altered by inhibitors of any of these enzymes. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Telavancin· 12.3 Pharmacokinetics · clearance not expected altered text · The clearance o... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +1 more | No reported alias | 0 identity 13 evidence |
PubMed 17485502 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 7 evidence |
PubMed 17923490 | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +2 more | No reported alias | 0 identity 6 evidence |
PubMed 29243921 | DistributionExposurePersistence Area Under Curve, Clearance, Volume Of Distribution | No reported alias | 0 identity 4 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 1 identity 2 evidence |
PubMed 17620377 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 3 evidence |
PubMed 18426954 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 2 evidence |
PubMed 17606689 | Distribution Plasma Protein Binding | No reported alias | 0 identity 1 evidence |
PubMed 17908947 | Distribution Plasma Protein Binding | No reported alias | 0 identity 1 evidence |
PubMed 18426898 | Distribution Plasma Protein Binding | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0013872' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.